Corvus Pharmaceuticals (CRVS) Q3 2026 earnings review
Corvus expands its immune trials, but key readouts slip to 2027
Corvus Pharmaceuticals, a clinical-stage developer of immune pills, doubled its research spending while its nearest drug readouts slipped into 2027. Quarterly net loss doubled to $20 million as research costs reached $18 million. Chief executive Richard A. Miller said its lymphoma and eczema trials remain on track, and third-quarter cash fell by only $12 million, beating what the company's own plan pointed to.
| Cash and marketable securities | $202.9M down $12.3M from last quarter |
|---|---|
| Research and development expense | $17.8M +110% from a year ago |
| Net loss | $20.3M $10.2M a year ago |
| Cash runway outlook | Unchanged funds operations into Q2 2028 |
⚖️ Verdict: ⚪ Neutral
The story is unchanged because trial execution progressed alongside minor schedule delays. Encouragingly, the first three patients in a rare immune disorder study completed a full year of treatment and stopped taking steroids, and a new skin trial started enrolling. The bad news: the first eczema readout from China moved from late 2026 to March 2027, and the US asthma trial start slipped into early 2027.
The question now is whether soquelitinib can prove durable skin clearance in larger blinded trials before Corvus needs more cash. Either the upcoming readouts confirm the small early studies, or results fade in larger groups while trial spending climbs toward the $31 million quarterly pace implied by the runway outlook. March 2027 eczema data from China will provide the first test.
🐂 Bull Case
New Skin Trial Starts and Rare Disease Works
Corvus is testing soquelitinib, an oral pill that blocks an immune enzyme called ITK, across multiple inflammatory diseases. Management wants to prove that blocking ITK calms overactive immune cells while boosting regulatory cells that stop inflammation.
This quarter the drugmaker began enrolling up to 25 patients in a Phase 1b trial for hidradenitis suppurativa (HS), a painful, scarring skin condition. In a separate government-run Phase 2 trial for Autoimmune Lymphoproliferative Syndrome (ALPS), a rare genetic immune disorder, the first three patients completed 360 days of treatment and were able to "discontinue background medications including steroids".
These updates matter because they show patients can tolerate the 200 mg twice-daily dose for a full year without severe side effects. Because all three ALPS patients improved, the government agency plans to transfer the trial application to Corvus so the company can add treatment centers and enroll children.
What to watch: initial efficacy and biomarker data from the HS skin trial in the first half of 2027. Strong skin clearance and regulatory T-cell increases would validate expanding the drug into broader inflammatory markets.
Cash Burn Stayed Below the Implied Plan
Corvus ended the quarter with $202.9 million in cash and marketable securities after raising $189.4 million in January 2026. The company reiterated its plan "to fund operations into the second quarter of 2028". By our math, exhausting that cash over the remaining six to seven quarters points to an average burn of about $31.2 million per quarter.
Actual net cash fell by only $12.3 million from last quarter's $215.2 million balance. Interest income of $1.9 million and a rise in unpaid bills buffered the $21.4 million operating loss, so the balance beat what the prior trajectory implied. That beat shows the cash cushion is comfortable today, though spending will rise as new trials fill up.
What to watch: quarterly net cash outflow in the fourth quarter as the asthma study prepares to launch. If quarterly burn stays near $15 million, the cash runway will stretch beyond the middle of 2028.
China Partner Matches US Patient Profiles
Corvus relies on Angel Pharmaceuticals, a Chinese biotech in which it holds a 49% stake, to run parallel trials in China. Angel is testing soquelitinib in moderate-to-severe atopic dermatitis, commonly known as eczema, across 48 patients in a Phase 1b study before adding 60 to 90 patients in Phase 2.
Angel finished enrolling the first 24 patients on schedule in September. Management said the patients' starting disease severity, age, and prior treatments match the 72 patients from Corvus's earlier US trial. Meanwhile, Memorial Sloan Kettering researchers showed "an inhibition of cancerous Th2 cells and a skewing to Th1 cells" in lymphoma biopsies, and the journal Blood published the final Phase 1 lymphoma results.
What to watch: topline eczema scores from Angel's first 24 patients in March 2027. Because the patient baselines match the US study, similar skin clearance would support the larger blinded US trial.
🐻 Bear Case
Key Clinical Timelines Slipped Into Next Year
"Our Phase 3 PTCL and Phase 2 atopic dermatitis clinical trials are on track and there has been strong interest in our new hidradenitis suppurativa trial," chief executive Richard A. Miller said. Miller added that the company is "positioned for a series of potentially significant data milestones across our soquelitinib development pipeline in 2027".
Yet every near-term readout and trial start originally planned for late 2026 moved into 2027 this quarter. Even though Angel finished enrolling Cohort 1 on time in September for a 12-week treatment regimen, Corvus pushed the data readout from late 2026 to March 2027. Both the US and Chinese asthma trials also slipped by a quarter.
- Angel eczema Cohort 1 data: now March 2027, pushed back from late 2026
- US Phase 2 asthma trial start: now by Q1 2027, pushed back from late 2026
- Angel China Phase 2 asthma trial start: now Q2 2027, pushed back from early 2027
These shifts matter because they continue a multi-quarter pattern of one-quarter delays across the pipeline. Investors now get zero clinical efficacy readouts in the second half of 2026, compressing all proof points into 2027 while trial spending climbs.
What to watch: whether Corvus doses the first US asthma patient before March 31, 2027. Another delay would show that managing four simultaneous trials is stretching the small team.
Trial Spending Doubles as Multiple Studies Ramp
Corvus is a clinical-stage company with no product sales, so its operating loss tracks its clinical trial activity. Running a global Phase 3 trial in peripheral T-cell lymphoma (PTCL), a blood cancer, alongside two skin trials is driving expenses sharply higher.
Research and development expenses jumped 110.3% from a year ago to $17.8 million, making up 83.2% of total operating costs by our math. Total operating expenses rose 102.1% from a year ago to $21.4 million, widening the quarterly net loss from $10.2 million to $20.3 million. Because the asthma trial has not even started, quarterly costs will climb further toward the $31.2 million average burn implied by the runway outlook.
What to watch: research and development spending in the fourth quarter. A jump above $22 million before the asthma study opens would increase the risk that Corvus needs another stock offering before Phase 3 readouts.
Risks this quarter didn't answer
Several standing clinical, competitive, and governance concerns received no new data in the third-quarter release.
- SIERRA1 eczema trial efficacy and competition: the 200-patient trial remains blinded until 2027, leaving open how a 12-week regimen compares with 16-week rival drugs.
- PTCL Phase 3 futility check: the release gave no enrollment count or date for the interim futility review previously projected for early 2027.
- Single-drug reliance and solid tumors: all trials test soquelitinib, and the release again omitted any mention of the previously planned solid-tumor study.
- Viral reactivation safety: no updated patient-day safety counts were given to test the theoretical Epstein-Barr virus risk from blocking ITK.
- Angel Pharma governance: Corvus booked a $0.9 million non-cash loss from its 49% stake in Angel, where Miller serves as both chief executive and chairman.
💲 Other KPIs
Weighted average diluted shares rose 11.7% from 82.8 million a year ago. The increase stems from the January 2026 stock offering that raised $189.4 million. The higher share count held the per-share loss increase to 83.3% ($0.22 vs $0.12) even though total net loss doubled.
Unpaid bills and accrued clinical trial liabilities rose 66.3% from $9.0 million at the end of 2025. Delaying cash payments for those rising trial bills helped keep third-quarter cash burn down at $12.3 million despite a $21.4 million operating loss.
Overhead and administrative costs grew 69.1% from $2.1 million a year ago, and rose 7.4% from $3.3 million last quarter. Total stock-based compensation across the company more than doubled from a year ago, climbing 133.3% from $1.2 million to $2.8 million.
🔮 Guidance
Unchanged. Corvus still expects its $202.9 million cash pile to fund operations into the second quarter of 2028, holding the target for a fourth straight quarter. By our math, that leaves an average cash burn of about $31.2 million per quarter over the next six to seven quarters, more than double this quarter's $12.3 million cash decline.
Delayed. Topline results from the first 24 eczema patients in China are now planned for March 2027 instead of late 2026. Although Angel finished enrolling the cohort on time in September for a 12-week treatment period, data cleaning and analysis pushed the release into the first quarter of next year.
Delayed. The US Phase 2 study testing soquelitinib in both T2 and non-T2 asthma patients is now scheduled to start by the first quarter of 2027 rather than late 2026. Angel Pharma's parallel Phase 2 asthma study in China also moved from early 2027 to the second quarter of 2027.
New. Following the start of patient enrollment this quarter, the drugmaker set its first timeline for initial safety, skin response, and biomarker data in the first half of 2027. The open-label study gives up to 25 patients a 200 mg twice-daily dose for 12 weeks.
❓ Key Questions
Why did Angel's 12-week eczema readout move to March?
Angel finished enrolling Cohort 1 in September 2026, so the 12-week treatment period ends in December. Investors need to know whether the March 2027 readout includes the 90-day off-drug follow-up period or reflects a delay in patient dosing.
When will the lymphoma Phase 3 futility check happen?
Management previously projected an independent futility check for the Phase 3 PTCL trial in the first quarter of 2027. The release did not mention that review, leaving unclear how fast progression events are accruing.
What happened to the solid-tumor clinical trial?
Corvus previously planned to test soquelitinib in solid tumors, and the release still mentions solid tumors in its background section. Management has not stated whether that study is cancelled or deferred to save cash.
How much will the new asthma trial add to burn?
By our math, the Q2 2028 cash runway allows average quarterly burn to rise from $12.3 million to about $31.2 million. Management has not broken down how much the new asthma and pediatric ALPS plans will cost.